Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658899 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CRD-4730 in CPVT
A Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Cardurion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 9
- Study locations
NCT06658899: Recruiting Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Cardurion Pharmaceuticals.
NCT06658899 is a Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia that is actively recruiting participants, run by Cardurion Pharmaceuticals. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06658899, a Phase 2 study of Catecholaminergic Polymorphic Ventricular Tachycardia, is actively recruiting participants, sponsored by Cardurion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Primary Outcome
The number and severity of treatment-emergent adverse events (TEAEs) related to study drug treatment
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRD-4730
Study Locations (9)
California
- Cardurion Investigative Site - San Francisco
North Carolina
- Cardurion Investigative Site - Morrisville
Texas
- Cardurion Investigative Site - Houston
Wisconsin
- Cardurion Investigative Site - Madison
British Columbia
- Cardurion Investigative Site - Vancouver
Other
- Cardurion Investigative Site - Saint-Herblain
Pavia
- Cardurion Investigative Site - Pavia
North Holland
- Cardurion Investigative Site - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT06658899 shows while recruiting
NCT06658899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Catecholaminergic Polymorphic Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06658899 lists 9 locations in 9 states (California, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT06658899 about?
NCT06658899 is a clinical study titled "A Phase 2 Study of CRD-4730 in CPVT". This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPV...
What is the current status of trial NCT06658899?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2025-12-01. Estimated completion is 2027-04.
What conditions does trial NCT06658899 study?
This clinical trial studies the following conditions: Catecholaminergic Polymorphic Ventricular Tachycardia.
What interventions are being tested in trial NCT06658899?
The interventions under investigation include: Placebo (DRUG), CRD-4730 (DRUG).
Who is sponsoring clinical trial NCT06658899?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658899 being conducted?
This trial has 9 study locations across California, North Carolina, Texas, Wisconsin, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Catecholaminergic Polymorphic Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06658899's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI